Related references
Note: Only part of the references are listed.Mutant Prevention Concentration-Based Pharmacokinetic/Pharmacodynamic Indices as Dosing Targets for Suppressing the Enrichment of Levofloxacin-Resistant Subpopulations of Staphylococcus aureus
Beibei Liang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Fluoroquinolone and Quinazolinedione Activities against Wild-Type and Gyrase Mutant Strains of Mycobacterium smegmatis
Muhammad Malik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Evaluation of the Clinical Efficacy of Pradofloxacin Tablets for the Treatment of Canine Pyoderma
Christina Restrepo et al.
JOURNAL OF THE AMERICAN ANIMAL HOSPITAL ASSOCIATION (2010)
Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance
Alexandre Wohlkonig et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2010)
Structural Basis of Gate-DNA Breakage and Resealing by Type II Topoisomerases
Ivan Laponogov et al.
PLOS ONE (2010)
Quinolones: Action and Resistance Updated
Karl Drlica et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2009)
A unified anti-mutant dosing strategy
Xilin Zhao et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Evaluation of pradofloxacin for the treatment of feline rhinitis
Miranda E. Spindel et al.
JOURNAL OF FELINE MEDICINE AND SURGERY (2008)
Retinal safety of a new fluoroquinolone, pradofloxacin, in cats: assessment with electroretinography
Andre Messias et al.
DOCUMENTA OPHTHALMOLOGICA (2008)
Quinolone-mediated bacterial death
Karl Drlica et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis
Deepak Almeida et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Mutant selection window hypothesis updated
Karl Drlica et al.
CLINICAL INFECTIOUS DISEASES (2007)
The mutant selection window in rabbits infected with Staphylococcus aureus
Junchang Cui et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Outlines of an exploding network of metabolites generated from the fluoroquinolone enrofloxacin by the brown rot fungus Gibeophyllum striatum
W. Karl et al.
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2006)
Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration
Sara K. Olofsson et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Comparative mutant prevention concentrations of pradofloxacin and other veterinary fluoroquinolones indicate differing potentials in preventing selection of resistance
HG Wetzstein
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy
DE Croisier et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia:: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants
D Croisier et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits
M Etienne et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Restricting the selection of antibiotic-resistant mutants: A general strategy derived from fluoroquinolone studies
XL Zhao et al.
CLINICAL INFECTIOUS DISEASES (2001)
Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria
G Sindelar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Share Paper
